Boston Scientific Corp. (BSX) recently entered into a four-year exclusive marketing agreement with Bladder Health Network (BHN). As per the agreement, the Urology and Women’s Health division of Boston Scientific will market BHN’s female urodynamic testing solutions in the United States. Financial terms of the agreement were not disclosed. 

BHN is a privately held organization that offers advanced testing solutions for urinary incontinence. The company offers an integrated diagnostic solutions platform that combines software, equipment, staffing, supplies and results analysis. This affords physicians and patients a greater access to testing, interpretation and treatment options. 

Urodynamics testing evaluates the function and efficiency of a patient’s urinary system by measuring the amount of pressure experienced by the bladder and urethra. It has been estimated that urinary incontinence affects one out of four women in the United States. Though not a life-threatening disease, it can significant diminish one’s quality of life. 

The new agreement enables Boston Scientific to offer a new professional testing and results interpretation platform for physicians treating urinary incontinence. This in turn reveals Boston Scientific’s strong commitment for the welfare of the women’s health. 

Boston Scientific manufactures medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors include Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ). 

Presently, we are ‘Neutral’ on Boston Scientific Corp.
Read the full analyst report on “BSX”
Read the full analyst report on “JNJ”
Read the full analyst report on “MDT”
Read the full analyst report on “ABT”
Read the full analyst report on “STJ”
Zacks Investment Research